Decheng Capital Management Iii (Cayman), LLC Neu Base Therapeutics, Inc. Transaction History

Decheng Capital Management Iii (Cayman), LLC

  • $181 Million
  • Q3 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 28, 2023
SELL
$0.13 - $3.05 $123,500 - $2.9 Million
-950,000 Reduced 95.0%
50,000 $93,000
Q1 2022

May 10, 2022
BUY
$1.26 - $2.95 $1.26 Million - $2.95 Million
1,000,000 New
1,000,000 $1.88 Million

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Decheng Capital Management Iii (Cayman), LLC Portfolio

Follow Decheng Capital Management Iii (Cayman), LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Decheng Capital Management Iii (Cayman), LLC, based on Form 13F filings with the SEC.

News

Stay updated on Decheng Capital Management Iii (Cayman), LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email